Ask AI

Optimizing Neoadjuvant Treatment in HER2+ Early-Stage Breast Cancer

Video
This activity is available for 0.50 CME/CE credit(s).

Released: October 08, 2026

Expiration: April 07, 2027

See Activity Collection

Neoadjuvant therapy has evolved into a platform for prognosis, treatment selection, and therapeutic innovation in HER2-positive breast cancer. This video module reviews the evidence for removing anthracyclines from routine neoadjuvant treatment, eliminating carboplatin, and potentially replacing chemotherapy with targeted treatments. The current landscape of personalized neo/adjuvant treatment selection relies on factors including initial disease burden, previous treatments, and residual disease burden.

Neoadjuvant Tx in HER2 Pos EBC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

A 52-year-old woman has newly diagnosed HER2-positive (IHC 3+), ER-negative/PR-negative stage III breast cancer with a 5.5-cm primary tumor and biopsy-confirmed axillary lymph node involvement. Which of the following is an FDA-approved neoadjuvant treatment option for this patient that demonstrated improved pCR rate compared to ddAC-THP in a phase III trial?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 50-year-old woman with node-positive, HER2-positive stage III breast cancer receives neoadjuvant TCHP. At surgery, she has residual invasive disease in both the breast and axillary lymph nodes. Given her high-risk of recurrence, which of the following adjuvant treatments would you choose for this patient to maximize invasive disease–free survival?

4.

How many people with breast cancer do you provide care for in a typical month?